Protollin: a novel adjuvant for intranasal vaccines (Q45021639)

8 December 2017

Protollin: a novel adjuvant for intranasal vaccines (English)

1 reference

8 December 2017

Taff Jones

1

1 reference

8 December 2017

Sonya Cyr

2

1 reference

8 December 2017

Francine Allard

3

1 reference

8 December 2017

Nathalie Bellerose

4

1 reference

8 December 2017

George H Lowell

5

1 reference

8 December 2017

David S Burt

6

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

8 December 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

8 December 2017

22

1 reference

8 December 2017

27-28

1 reference

8 December 2017

3691-3697

1 reference

The instructive role of innate immunity in the acquired immune response

8 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Role of secretory antibodies in the defence against infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

New generation of mucosal adjuvants for the induction of protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Recent advances in vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Determinants of immunity to influenza infection in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

The role of porins in neisserial pathogenesis and immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Taking toll: lipid A mimetics as adjuvants and immunomodulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Mechanisms of viral clearance and persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.035

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.03.035

1 reference

8 December 2017

1 reference